英文名稱 | Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372) |
---|---|
中文名稱 | 埃萬妥單抗 |
CAS號 | 2171511-58-1 |
儲存條件 | -20°C for 3 years | In solvent: -80°C for 1 year |
英文名稱 | Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372) |
---|---|
中文名稱 | 埃萬妥單抗 |
CAS號 | 2171511-58-1 |
儲存條件 | -20°C for 3 years | In solvent: -80°C for 1 year |
Amivantamab (JNJ-61186372) is a fully human EGFR-MET bispecific antibody that combats resistance in NSCLC through multifaceted mechanisms: ligand blockade, receptor degradation, and immune cell activation, including ADCC and trogocytosis. This innovative approach targets both primary and acquired resistance, offering a new therapeutic avenue for patients with EGFR and MET aberrations.
PMID: 34339292 PMCID: PMC8791812 DOI: 10.1200/JCO.21.00662
PMID: 32414908 DOI: 10.1158/2159-8290.CD-20-0116